Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 1 , Pages 33-41 , March 2007

Biochemistry of neuroendocrine tumours

  • Wouter W. de Herder, MD, PhD (Consultant Endocrinologist)

      Affiliations

    • Corresponding Author InformationTel.: +31 10 4635950; Fax: +31 10 4633268.

References 

  1. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Reviews. 2004;25:458–511
  2. de Herder WW, Krenning EP, van Eijck CH, Lamberts SW. Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas. Endocrine-Related cancer. 2004;11:19–34
  3. Caplin ME, Buscombe JR, Hilson AJ, et al. Carcinoid tumour. Lancet. 1998;352:799–805
  4. Kulke MH, Mayer RJ. Carcinoid tumors. The New England Journal of Medicine. 1999;340:858–868
  5. de Herder WW. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome). Best Practice & Research. Clinical Gastroenterology. 2005;19:705–715
  6. Quaedvlieg PF, Lamers CB, Taal BG. Carcinoid heart disease: an update. Scandinavian Journal of Gastroenterology. Supplement. 2002;236:66–71
  7. Zuetenhorst JM, Bonfrer JM, Korse CM, et al. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer. 2003;97:1609–1615
  8. Feldman JM, Lee EM. Serotonin content of foods: effect on urinary excretion of 5-hydroxyindoleacetic acid. The American Journal of Clinical Nutrition. 1985;42:639–643
  9. Kema IP, de Vries EG, Muskiet FA. Measurement of 5-HIAA in urine. Annals of Clinical Biochemistry. 1995;32:102–104
  10. Kema IP, Meijer WG, Meiborg G, et al. Profiling of tryptophan-related plasma indoles in patients with carcinoid tumors by automated, on-line, solid-phase extraction and HPLC with fluorescence detection. Clinical Chemistry. 2001;47:1811–1820
  11. Kema IP, de Vries EG, Muskiet FA. Clinical chemistry of serotonin and metabolites. Journal of Chromatography. B, Biomedical Sciences and Applications. 2000;747:33–48
  12. Meijer WG, Kema IP, Volmer M, et al. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clinical Chemistry. 2000;46:1588–1596
  13. Kema IP, de Vries EG, Slooff MJ, et al. Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. Clinical Chemistry. 1994;40:86–95
  14. Service FJ, Natt N, Thompson GB, et al. Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. The Journal of Clinical Endocrinology and Metabolism. 1999;84:1582–1589
  15. Service FJ. Hypoglycemic disorders. The New England Journal of Medicine. 1995;332:1144–1152
  16. Service FJ, Natt N. The prolonged fast. The Journal of Clinical Endocrinology and Metabolism. 2000;85:3973–3974
  17. Service FJ. Clinical review 42: hypoglycemias. The Journal of Clinical Endocrinology and Metabolism. 1993;76:269–272
  18. de Herder WW. Insulinoma. Neuroendocrinology. 2004;80(supplement 1):20–22
  19. van der Wal BC, de Krijger RR, de Herder WW, et al. Adult hyperinsulinemic hypoglycemia not caused by an insulinoma: a report of two cases. Virchows Archiv. 2000;436:481–486
  20. Service FJ, O'Brien PC. Increasing serum betahydroxybutyrate concentrations during the 72-hour fast: evidence against hyperinsulinemic hypoglycemia. The Journal of Clinical Endocrinology and Metabolism. 2005;90:4555–4558
  21. Service FJ. Classification of hypoglycemic disorders. Endocrinology and Metabolism Clinics of North America. 1999;28:501–517
  22. Kao PC, Taylor RL, Service FJ. Proinsulin by immunochemiluminometric assay for the diagnosis of insulinoma. The Journal of Clinical Endocrinology and Metabolism. 1994;78:1048–1051
  23. O'Brien T, O'Brien PC, Service FJ. Insulin surrogates in insulinoma. The Journal of Clinical Endocrinology and Metabolism. 1993;77:448–451
  24. Piovesan A, Pia A, Visconti G, et al. Proinsulin-secreting neuroendocrine tumor of the pancreas. Journal of Endocrinological Investigation. 2003;26:758–761
  25. Shimizu T, Sasakuma F, Ishikawa O, et al. Assessment of immunoassays for insulin in diagnostic tests for insulinoma. Diabetes Research and Clinical Practice. 1994;26:149–154
  26. Wiesli P, Brandle M, Zapf J, et al. Assessment of hyperinsulinaemia at the termination of the prolonged fast. Clinica Chimica Acta. 2004;342:227–231
  27. Vezzosi D, Bennet A, Fauvel J, et al. Insulin levels measured with an insulin-specific assay in patients with fasting hypoglycaemia related to endogenous hyperinsulinism. European Journal of Endocrinology. 2003;149:413–419
  28. Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Current Gastroenterology Reports. 2004;6:454–463
  29. Jensen RT. Gastrinomas: advances in diagnosis and management. Neuroendocrinology. 2004;80(supplement 1):23–27
  30. Dockray GJ. Clinical endocrinology and metabolism. Gastrin. Best Practice & Research. Clinical Endocrinology & Metabolism. 2004;18:555–568
  31. Stridsberg M, Eriksson B, Oberg K, Janson ET. A panel of 13 region-specific radioimmunoassays for measurements of human chromogranin B. Regulatory Peptides. 2005;125:193–199
  32. Kolby L, Bernhardt P, Sward C, et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regulatory Peptides. 2004;120:269–273
  33. Seregni E, Ferrari L, Bajetta E, et al. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Annals of Oncology. 2001;12(supplement 2):S69–S72
  34. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. The Journal of Clinical Endocrinology and Metabolism. 1997;82:2622–2628
  35. Stridsberg M, Oberg K, Li Q, et al. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. The Journal of Endocrinology. 1995;144:49–59
  36. Modlin IM, Latich I, Zikusoka M, et al. Gastrointestinal carcinoids: the evolution of diagnostic strategies. Journal of Clinical Gastroenterology. 2006;40:572–582
  37. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62(supplement 1):33–38
  38. Stridsberg M. The use of chromogranin, synaptophysin and islet amyloid polypeptide as markers for neuroendocrine tumours. Upsala Journal of Medical Sciences. 1995;100:169–199
  39. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. The New England Journal of Medicine. 1986;314:1145–1151
  40. Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocrine Reviews. 1991;12:181–187
  41. Baudin E, Gigliotti A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. British Journal of Cancer. 1998;78:1102–1107
  42. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86:858–865
  43. Meijer WC, van Veldhuisen DJ, Kema IP, et al. Cardiovascular abnormalities in patients with a carcinoid syndrome. The Netherlands Journal of Medicine. 2002;60:10–16
  44. Meijer WG, Copray SC, Hollema H, et al. Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas. Clinical Chemistry. 2003;49:586–593
  45. Turner GB, Johnston BT, McCance DR, et al. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut. 2006;55:1586–1591
  46. Panzuto F, Severi C, Cannizzaro R, et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. Journal of Endocrinological Investigation. 2004;27:6–11
  47. Corbetta S, Peracchi M, Cappiello V, et al. Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma. The Journal of Clinical Endocrinology and Metabolism. 2003;88:3117–3120
  48. Tsolakis AV, Portela-Gomes GM, Stridsberg M, et al. Malignant gastric ghrelinoma with hyperghrelinemia. The Journal of Clinical Endocrinology and Metabolism. 2004;89:3739–3744
  49. Pavel ME, Hoppe S, Papadopoulos T, et al. Adrenomedullin is a novel marker of tumor progression in neuroendocrine carcinomas. Hormone and Metabolic Research. 2006;38:112–118

PII: S1521-690X(06)00111-4

doi: 10.1016/j.beem.2006.12.002

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 1 , Pages 33-41 , March 2007

Article Tools